

# Antonio J Carcas Sansuñin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8054032/publications.pdf>

Version: 2024-02-01

104  
papers

2,544  
citations

236612

25  
h-index

223531

46  
g-index

116  
all docs

116  
docs citations

116  
times ranked

4450  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceuticals</i> , 2022, 15, 78.	1.7	8
2	Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 1139.	1.0	7
3	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. <i>Nature Biotechnology</i> , 2022, 40, 1680-1689.	9.4	29
4	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , 2021, 76, 920-929.	2.7	60
5	Health Care Workersâ€™ Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e23441.	2.1	2
6	Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. <i>Clinical Therapeutics</i> , 2021, 43, e86-e102.	1.1	4
7	Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2949.	1.0	4
8	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 783-792.	4.6	62
9	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 121-130.	6.3	316
10	Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Pharmacology</i> , 2021, 12, 717932.	1.6	4
11	Inhaled Methoxyflurane Provides Greater Analgesia and Faster Onset of Action Versus Standard Analgesia in Patients With Trauma Pain: InMEDIATE: A Randomized Controlled Trial in Emergency Departments. <i>Annals of Emergency Medicine</i> , 2020, 75, 315-328.	0.3	38
12	Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data. <i>Frontiers in Pharmacology</i> , 2020, 11, 602841.	1.6	18
13	Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. <i>Scientific Reports</i> , 2020, 10, 7542.	1.6	12
14	A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 466.	0.7	38
15	Strategy to effectively and efficiently implement Voriconazole pharmacogenetics in clinical practice. <i>Pharmacogenomics</i> , 2020, 21, 647-649.	0.6	5
16	A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. <i>Journal of Clinical Medicine</i> , 2020, 9, 1733.	1.0	218
17	The need to implement non-industry COVID-19 clinical trials in non-high-income countries. <i>Journal of Global Health</i> , 2020, 10, 010351.	1.2	0
18	In reply:. <i>Annals of Emergency Medicine</i> , 2020, 75, 551-552.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. <i>BMJ Open</i> , 2020, 10, e037443.	0.8	8
20	Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 463-470.	1.1	17
21	Severe Hyponatremia Is Often Drug Induced: 10-Year Results of a Prospective Pharmacovigilance Program. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1362-1379.	2.3	21
22	Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing <i>Klebsiella pneumoniae</i> ST405 strains. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 19, 241-251.	0.9	4
23	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	2.3	23
24	Weight of <i>ABCB1</i> and <i>POR</i> genes on oral tacrolimus exposure in <i>CYP3A5</i> nonexpressor pediatric patients with stable kidney transplant. <i>Pharmacogenomics Journal</i> , 2018, 18, 180-186.	0.9	12
25	Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. <i>Clinical and Translational Science</i> , 2018, 11, 189-199.	1.5	37
26	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 317-325.	2.3	46
27	Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. <i>Journal of Psychopharmacology</i> , 2018, 32, 1212-1222.	2.0	10
28	Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction. <i>Metabolomics</i> , 2018, 14, 70.	1.4	5
29	Efficient diagnosis and treatment of acute paracetamol poisoning: cost-effectiveness analysis of approaches based on a hospital toxicovigilance program. <i>Emergencias</i> , 2018, 30, 169-176.	0.6	1
30	Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1921-1931.	1.1	9
31	Influence of two variants of <i>CYP450</i> oxidoreductase on the stable dose of acenocoumarol in a Spanish population. <i>Pharmacogenomics</i> , 2017, 18, 797-805.	0.6	1
32	Who is willing to participate in low-risk pragmatic clinical trials without consent?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1557-1563.	0.8	5
33	Comparative effectiveness medicines research cannot assess efficacy. <i>Journal of Clinical Epidemiology</i> , 2017, 92, 129.	2.4	1
34	Hepatotoxicity induced by acute and chronic paracetamol overdose in children: Where do we stand?. <i>World Journal of Pediatrics</i> , 2017, 13, 76-83.	0.8	7
35	Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 400-415.	1.1	27
36	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. <i>Pharmacological Research</i> , 2017, 115, 168-178.	3.1	61

#	ARTICLE	IF	CITATIONS
37	Patients' beliefs regarding informed consent for low-risk pragmatic trials. BMC Medical Research Methodology, 2017, 17, 145.	1.4	7
38	Appropriate use of red blood cell transfusion in emergency departments: a study in five emergency departments. Blood Transfusion, 2017, 15, 199-206.	0.3	36
39	A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS ONE, 2016, 11, e0150456.	1.1	17
40	Outcomes and Costs of Poisoned Patients Admitted to an Adult Emergency Department of a Spanish Tertiary Hospital: Evaluation through a Toxicovigilance Program. PLoS ONE, 2016, 11, e0152876.	1.1	14
41	Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatric Hematology and Oncology, 2016, 33, 441-456.	0.3	8
42	Limited sampling strategies for once daily tacrolimus exposure monitoring. European Journal of Clinical Pharmacology, 2016, 72, 773-774.	0.8	0
43	Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. International Journal of Antimicrobial Agents, 2016, 47, 410-411.	1.1	2
44	Implementación de la farmacogenética en la práctica clínica: hacia las estrategias de genotipado anticipado. IJ Clinical Pharmacology, 2016, 1, .	0.0	2
45	Uam Course on Good Clinical Practice (Gcps) for Investigators: A 3 Years Experience. Clinical Therapeutics, 2015, 37, e129.	1.1	0
46	Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice. Medicina Clínica (English Edition), 2015, 145, 452-457.	0.1	1
47	A Pharmacovigilance Program from Laboratory Signals In Hospitalized Patients: Results Of 2014. Clinical Therapeutics, 2015, 37, e137.	1.1	0
48	Non-Chemotherapy-Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 399-408.	1.2	8
49	Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand?. Regulatory Toxicology and Pharmacology, 2015, 72, 370-378.	1.3	17
50	High dose favipiravir: first experience in a patient with Ebola. Clinical Therapeutics, 2015, 37, e15-e16.	1.1	3
51	Sat-Hulp Toxicovigilance program: Results of 30 Months. Clinical Therapeutics, 2015, 37, e128.	1.1	0
52	Pharmacogenetic Implementation In The Routine Clinical Practice: Design of A Multicenter Pilot Clinical Trial. Clinical Therapeutics, 2015, 37, e129-e130.	1.1	0
53	Cytochrome P450 Oxidoreductase Contribution On An Acenocoumarol Dosing Algorithm. Clinical Therapeutics, 2015, 37, e131.	1.1	0
54	Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respiratory Medicine, the, 2015, 3, 554-562.	5.2	113

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetics of quetiapine in healthy volunteers. <i>International Clinical Psychopharmacology</i> , 2015, 30, 82-88.	0.9	23
56	Screening and Recruitment Procedures of Healthy Volunteers In A Phase I Clinical Trial Unit: Experience In 64 Bioequivalence Studies. <i>Clinical Therapeutics</i> , 2015, 37, e129.	1.1	0
57	Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. <i>Pediatric Nephrology</i> , 2014, 29, 117-123.	0.9	13
58	Limited sampling strategies for tacrolimus exposure (AUC <sub>0-24</sub> ) prediction after Prograf <sup>®</sup> and Advagraf <sup>®</sup> administration in children and adolescents with liver or kidney transplants. <i>Transplant International</i> , 2014, 27, 939-948.	0.8	12
59	Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. <i>Pharmacogenomics Journal</i> , 2013, 13, 452-455.	0.9	12
60	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1203-1214.	0.6	9
61	A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism. <i>Clinical Biochemistry</i> , 2013, 46, 167-169.	0.8	6
62	Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 97-110.	0.8	18
63	Conversion from Prograf to Advagraf in Adolescents with stable liver transplants: Comparative pharmacokinetics and 1-year follow-up. <i>Liver Transplantation</i> , 2013, 19, 1151-1158.	1.3	11
64	A Preliminary Model to Avoid the Overestimation of Sample Size in Bioequivalence Studies. <i>Drug Research</i> , 2013, 63, 98-103.	0.7	2
65	Vancomycin-Induced Acute Kidney Injury Detected by a Prospective Pharmacovigilance Program From Laboratory Signals. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 360-366.	1.0	10
66	Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 239.	0.7	15
67	An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. <i>PLoS ONE</i> , 2012, 7, e41360.	1.1	52
68	Use of antifungal agents in pediatric and adult high-risk areas. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 337-347.	1.3	7
69	Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. <i>European Journal of Pharmacology</i> , 2010, 626, 200-204.	1.7	43
70	Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 694-702.	1.1	70
71	DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in an 11-year-old caucasian boy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 365-370.	0.7	27
72	A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 74-86.	2.3	67

#	ARTICLE	IF	CITATIONS
73	Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 635-9.	1.4	6
74	Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Tertiary Spanish Hospital. <i>Current Clinical Pharmacology</i> , 2010, 5, 288-297.	0.2	67
75	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. <i>Journal of Medical Virology</i> , 2009, 81, 211-216.	2.5	5
76	CYP2C9 polymorphism in five autochthonous population of the same geographic area (Spanish) Tj ETQq0 0 0 rgBT /Qverlock <sub>3,1</sub> 9 10 Tf 50 6	3.1	27
77	Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. <i>Pharmacological Research</i> , 2009, 59, 393-398.	3.1	27
78	Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 436-442.	1.0	67
79	The importance of sample size, log-mean ratios, and intrasubject variability in the acceptance criteria of 108 bioequivalence studies. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 783-793.	0.8	9
80	Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1031-1032.	0.8	26
81	Sublingual administration of tacrolimus in a renal transplant patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 87-89.	0.7	20
82	Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 393-396.	0.7	58
83	A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 453-460.	1.1	3
84	Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against <i>Streptococcus pneumoniae</i> after administration of a single oral dose of pharmacokinetically enhanced 2000/125%mg co-amoxiclav to healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 742-747.	1.3	4
85	Pulmonary Damage and Bacterial Load in Assessment of the Efficacy of Simulated Human Treatment-Like Amoxicillin (2,000 Milligrams) Therapy of Experimental Pneumococcal Pneumonia Caused by Strains for Which Amoxicillin MICs Differ. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 996-1001.	1.4	5
86	Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 280-287.	0.9	164
87	Urinary Concentrations and Bactericidal Activity Against Amoxicillin-Nonsusceptible Strains of <i>Escherichia coli</i> with Single-Dose, Oral, Sustained-Release Amoxicillin/Clavulanic Acid: A Phase I, Open-Label, Noncomparative Clinical Trial in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2005, 27, 1043-1049.	1.1	9
88	Bactericidal activity of amoxicillin against non-susceptible <i>Streptococcus pneumoniae</i> in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125%mg sustained-release co-amoxiclav formulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 1148-1151.	1.3	23
89	PHASE I PHARMACOKINETIC STUDY OF A SINGLE INTRAVESICAL INSTILLATION OF GEMCITABINE ADMINISTERED IMMEDIATELY AFTER TRANSURETHRAL RESECTION PLUS MULTIPLE RANDOM BIOPSIES IN PATIENTS WITH SUPERFICIAL BLADDER CANCER. <i>Journal of Urology</i> , 2004, 172, 485-488.	0.2	34
90	Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 169-175.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Does Acetaminophen Interfere in the Antibiotic Treatment of Acute Otitis Media Caused by a Penicillin-Resistant Pneumococcus Strain? A Gerbil Model. <i>Pediatric Research</i> , 2003, 54, 913-918.	1.1	5
92	Comparison of Lormetazepam Solution and Capsules in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2002, 22, 859-866.	1.1	2
93	Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 113-119.	0.7	12
94	Antibacterial Properties of Gemifloxacin and Trovafloxacin in Urine Ex Vivo: Phase I Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1876-1878.	1.4	10
95	Cefminox versus Metronidazole plus Gentamicin in Intra-abdominal Infections: A Prospective Randomized Controlled Clinical Trial. <i>Infection</i> , 2000, 28, 318-322.	2.3	10
96	Average bioequivalence of two oral formulations of ticlopidine in healthy volunteers. <i>Current Therapeutic Research</i> , 2000, 61, 523-533.	0.5	1
97	Digoxin Level and Clinical Manifestations as Determinants in the Diagnosis of Digoxin Toxicity. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 163-168.	1.0	29
98	Tobramycin penetration into epithelial lining fluid of patients with pneumonia. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 245-250.	2.3	71
99	Comparative Bioavailability of Two Oral 875/125mg Sachet Formulations of Amoxicillin/Clavulanic Acid in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 1999, 18, 217-224.	1.1	4
100	Evaluation of Sex Differences in the Pharmacokinetics of Ranitidine in Humans. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 748-751.	1.0	10
101	Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid. <i>Annals of Pharmacotherapy</i> , 1996, 30, 148-150.	0.9	12
102	Measurement of tobramycin in bronchoalveolar lavage fluid by a modified fluorescence polarization immunoassay. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 1111-1113.	1.3	7
103	Activated charcoal increases digoxin elimination in patients. <i>International Journal of Cardiology</i> , 1995, 48, 27-30.	0.8	31
104	Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 91-101.	1.3	8